The complaint

Baxter Healthcare Corp., Baxter International Inc. and Baxter Healthcare SA v. Sagent Pharmaceuticals (Inc.) and Gland Pharma Limited, No. 1:26-cv-01490 (D. Del.), is a 21-page complaint filed November 19, 2026, Document 1, with a jury demand. Baxter Healthcare Corp. is a Delaware corporation with offices in Deerfield, Illinois. It holds NDA No. 214313 and is a wholly-owned subsidiary of Baxter International Inc., which is also a Delaware corporation with offices in Deerfield, Illinois. Baxter Healthcare SA is a corporation organized under the laws of Switzerland, with offices in Opfikon, Switzerland, and is a wholly-owned subsidiary of Baxter International Inc. The complaint alleges, on information and belief, that Sagent Pharmaceuticals (Inc.) is a Wyoming corporation with a business address in Schaumburg, Illinois, and that Gland Pharma Limited is a corporation organized under the laws of India with its principal place of business in Hyderabad, India.

The complaint says the action arises from ANDA No. 219692, submitted under 21 U.S.C. 355(j)(2)(A), seeking approval to manufacture and sell norepinephrine bitartrate in 5% dextrose injection at 16 mcg/mL and 32 mcg/mL. It says the ANDA relies on investigations in Baxter's NDA No. 214313 for norepinephrine bitartrate in 5% dextrose injection at eq. 16 mcg/mL (4 mg/250 mL), eq. 32 mcg/mL (8 mg/250 mL), and eq. 64 mcg/mL (16 mg/250 mL). It says Sagent, in collaboration with Gland, sought and received approval to manufacture and sell the ANDA product before U.S. Patents 12,290,494 and 12,714,681 expire. It alleges, on information and belief, that the FDA approved the ANDA on August 11, 2025. It says Sagent has informed Baxter that Sagent intends to distribute and sell the ANDA product throughout the United States, including in Delaware, beginning on or after December 1, 2026. It alleges, on information and belief, that the defendants acted collaboratively in preparing, submitting, and filing the ANDA, and that they are in the business of developing, manufacturing, marketing, distributing, and directly and/or indirectly selling generic pharmaceutical products throughout the United States, including in Delaware, and of importing generic pharmaceutical products into the United States, including into Delaware.

The complaint alleges subject-matter jurisdiction under 28 U.S.C. 1331 and 1338(a). It says that on October 21, 2026, Sagent confirmed that it consents to being sued in the District of Delaware for this litigation. It alleges personal jurisdiction over Gland under Federal Rule of Civil Procedure 4(k)(1) and/or 4(k)(2). It alleges that venue is proper as to Sagent under 28 U.S.C. 1400(b) and as to Gland under 28 U.S.C. 1391(b) and/or 1391(c).

The NDA product and the patents

The complaint says NDA No. 214313 is approved as a catecholamine for treatment of severe, acute hypotension. It says the FDA approved the 16 mcg/mL strength and the 32 mcg/mL strength on January 15, 2021, and the 64 mcg/mL strength on November 21, 2023. It says Baxter launched the 16 mcg/mL and 32 mcg/mL strengths in September 2021 as the first and only ready-to-use premixed norepinephrine in dextrose product in the United States, and launched the 64 mcg/mL strength on January 26, 2024. It says that, under 21 U.S.C. 355(b)(1), the '494 patent and the '681 patent are listed in the Orange Book for the 16 mcg/mL and 32 mcg/mL strengths. It also says U.S. Patent 12,097,170 (the '170 patent), the '494 patent, and the '681 patent were listed for those strengths on September 30, 2024, May 16, 2025, and September 14, 2026, respectively.

The complaint says Baxter International Inc. and Baxter Healthcare SA are the assignees of the patents in suit. It says U.S. Patent 12,290,494, titled Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation, issued on May 6, 2025, and that U.S. Patent 12,714,681, with the same title, issued on August 25, 2026. The complaint attaches the '494 patent as Exhibit A and the '681 patent as Exhibit B. It says the '170 patent, titled Packaged, Sealed Container System for Stable Storage of an Oxygen Sensitive Pharmaceutical Formulation, issued on September 24, 2024, to Baxter International Inc. and Baxter Healthcare SA. The complaint's two counts assert the '494 and '681 patents.

Claim 1 of the '681 patent

The complaint states that the ANDA product will infringe claims 1-20 of the '681 patent, and it uses claim 1 as the example for this complaint, with further information to be provided later. Claim 1 covers a packaged, sealed container system for stable storage of a ready-to-use, stable norepinephrine formulation of about 0.015 mg/ml to about 0.035 mg/ml norepinephrine, in the form of norepinephrine bitartrate monohydrate, with dextrose and a pH between 3.4 and 4.0, free of an antioxidant and without sodium chloride. The primary container is an intravenous (IV) bag. A secondary container, comprising a first flexible sheet layer, an opposing second flexible sheet layer, and a seal along their common peripheral edge, encloses the bag and an oxygen scavenger that is in fluid communication with the bag's contents. The claim also requires that the formulation retain at least about 90% of an initial activity, measured by an initial and a final amount of R-norepinephrine, after storage for at least 120 days at 25° C. The complaint alleges, on information and belief, that the ANDA product meets each of those elements, including that the package insert states that the product contains norepinephrine bitartrate monohydrate.

The notice letters

The complaint describes two letters from Sagent. A letter dated October 3, 2024, which it calls the 2024 Notice Letter, purported to notify Baxter that the ANDA contains certifications under 21 U.S.C. 355(j)(2)(A)(vii)(IV), which the complaint calls a paragraph IV certification, with regard to the '170 patent. A letter dated June 18, 2025, which it calls the 2025 Notice Letter, purported to notify Baxter that Sagent had amended the ANDA to contain a certification under 21 U.S.C. 355(j)(2)(A)(vii)(IV), which the complaint calls a paragraph IV certification, with regard to the '494 patent. The complaint says the letters identify an agent authorized to accept service of process for Sagent and/or Gland, and that both letters state that the agent is authorized to accept service for Gland with respect to ANDA No. 219237. It says the ANDA number for the product is 219692, and that the plaintiffs construe the letters as referring to ANDA No. 219692. It says Sagent has been aware of the '494 patent since at least June 18, 2025, and that on August 25, 2026 the plaintiffs notified Sagent of the '681 patent, so Sagent has been aware of the '681 patent since at least that date. It alleges, on information and belief, that Gland has been aware of the '494 patent since at least June 18, 2025, and of the '681 patent since at least August 25, 2026.

The complaint says that on September 30, 2026, Sagent sent Baxter an email stating: "By this email, Sagent hereby provides Baxter with 21 days advance notice of Sagent's launch of Sagent's norepinephrine in dextrose (4 mg/250 ml and 8 mg/250 ml) products that are the subject of Defendants' ANDA No. 219692." It says that on October 2, 2026, Sagent notified Baxter that it will not launch "its product until December 1, 2026." It says that on November 3, 2026, Sagent produced a purported copy of ANDA No. 219692 and related FDA correspondence to counsel for Baxter. It says that on November 16, 2026, Sagent informed Baxter by email that it had shipped 5 samples each of the 4 mg/250 mL and 8 mg/250 mL strengths on Friday, November 13, 2026 to Baxter.

The two counts

The first count, infringement of the '494 patent, begins at paragraph 80. The complaint alleges, on information and belief, that the defendants submitted a paragraph IV certification to the '494 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the ANDA product before that patent expires. It states that including that certification in the ANDA is an act of infringement of one or more claims of the '494 patent under 35 U.S.C. 271(e)(2)(A), directly and/or indirectly, literally or under the doctrine of equivalents, including by inducement and/or contributory infringement. It alleges, on information and belief, that commercial manufacture, use, sale, offer for sale, and/or importation of the ANDA product will infringe one or more claims of the '494 patent under 35 U.S.C. 271(a), 271(b), and/or 271(c). It alleges, on information and belief, that the defendants know of the '494 patent at least because it is listed in the Orange Book for Baxter's product, and that they acted without a reasonable basis for believing that they would not be liable for infringement of the '494 patent, rendering the case exceptional under 35 U.S.C. 285.

The second count, infringement of the '681 patent, begins at paragraph 89. The complaint alleges, on information and belief, that the defendants submitted a paragraph IV certification to the '170 patent and the '494 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the ANDA product before the '681 patent expires. It states that the submission, filing, and maintenance of the ANDA, for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the ANDA product before the '681 patent expires, is an act of infringement of the '681 patent under 35 U.S.C. 271(e)(2)(A), directly and/or indirectly, literally or under the doctrine of equivalents, including by inducement and/or contributory infringement. It alleges, on information and belief, that commercial manufacture, use, sale, offer for sale, and/or importation will infringe one or more claims of the '681 patent under 35 U.S.C. 271(a), 271(b), and/or 271(c). It alleges, on information and belief, that the defendants have been aware of the '681 patent since at least August 25, 2026, including through the plaintiffs' express notice to Sagent, that they know the patent is listed in the Orange Book, and that they know commercial manufacture, use, sale, offer for sale, and/or importation will infringe one or more claims. The complaint says that, despite that knowledge, Sagent has represented that it will launch the ANDA product in the United States beginning as early as December 1, 2026, and that the defendants' deliberate infringement, despite their knowledge of the patent and of their infringement, constitutes willful infringement and provides a basis for enhanced damages under 35 U.S.C. 284. The complaint says that the defendants are imminently going to act without a reasonable or meritorious basis for believing that they would not be liable for infringement of the '681 patent, rendering the case exceptional under 35 U.S.C. 285. Each count states that the alleged infringement will cause irreparable harm for which there is no adequate remedy at law unless the defendants are preliminarily and permanently enjoined.

The relief requested

For the '494 patent, the prayer asks for a judgment that the patent is valid and enforceable. It asks for a judgment that, under 35 U.S.C. 271(e)(2)(A), submitting the ANDA to the FDA and filing it with a paragraph IV certification, to obtain approval for commercial manufacture, use, sale, offer for sale, and/or importation in the United States of the product that is the subject of the ANDA, was an act of infringement of the '494 patent by the defendants directly and/or indirectly, including by inducement and/or contributory infringement. It asks for a judgment that, under 35 U.S.C. 271(a), 271(b), and/or 271(c), commercial manufacture, use, sale, offer for sale, and/or importation in the United States of the ANDA product before the patent expires, including any regulatory extensions, will constitute an act of infringement by the defendants directly and/or indirectly, including by inducement and/or contributory infringement. It asks for an order under 35 U.S.C. 271(e)(4)(A) that the effective date of any approval of the ANDA product be no earlier than the date the '494 patent expires, including any regulatory extensions. It asks for a judgment under 35 U.S.C. 271(e)(4)(B) and 283 preliminarily and permanently enjoining the defendants and their officers, agents, servants, employees, and attorneys, and those persons in active concert or participation or privity with them or any of them, from that commercial activity until the '494 patent expires, including any regulatory extensions. It asks for damages or other monetary relief under 35 U.S.C. 271(e)(4)(C) and 284 if the defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of the ANDA that infringes the '494 patent. It asks for a judgment declaring that infringement of the '494 patent is willful if the defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of the ANDA that infringes it.

For the '681 patent, the prayer asks for a judgment that the patent is valid and enforceable. It asks for a judgment that, under 35 U.S.C. 271(e)(2)(A), submitting the ANDA to the FDA and filing it, to obtain approval for commercial manufacture, use, sale, offer for sale, and/or importation in the United States of the product that is the subject of the ANDA, was an act of infringement of the '681 patent by the defendants directly and/or indirectly, including by inducement and/or contributory infringement. It asks for a judgment that, under 35 U.S.C. 271(a), 271(b), and/or 271(c), commercial manufacture, use, sale, offer for sale, and/or importation in the United States of the ANDA product before the patent expires, including any regulatory extensions, will constitute an act of infringement by the defendants directly and/or indirectly, including by inducement and/or contributory infringement. It asks for an order under 35 U.S.C. 271(e)(4)(A) that the effective date of any approval of the ANDA product be no earlier than the date the '681 patent expires, including any regulatory extensions. It asks for a judgment under 35 U.S.C. 271(e)(4)(B) and 283 preliminarily and permanently enjoining the defendants and their officers, agents, servants, employees, and attorneys, and those persons in active concert or participation or privity with them or any of them, from that commercial activity until the '681 patent expires, including any regulatory extensions. It asks for damages or other monetary relief under 35 U.S.C. 271(e)(4)(C) and 284, including a judgment finding willful infringement and awarding up to treble damages, for any and all commercial manufacture, use, sale, offer to sell, and/or importation of any product that is the subject of the ANDA that infringes the '681 patent. The prayer also asks for taxable costs, prejudgment and post-judgment interest, a declaration under 35 U.S.C. 285 that this is an exceptional case and an award of attorneys' fees and related nontaxable expenses, and such other and further relief as the court may deem just and proper.

What to watch next

Watch for an answer or a Rule 12 motion, and for any commercial launch on or after December 1, 2026, the date the complaint says Sagent has given Baxter. The case can end at any time, including by settlement or voluntary dismissal.